SecBot SecBot

PLX drug pipeline

$3.03
−0.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
4
1 mixed · 3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketIf Phase 2 data in H2 2027 is positive, a Phase 3 program would follow, meaning potential FDA approval/commercialization is likely several years away, likely 2029-2031 at the earliest.

PRX-115 Updated Nov 11

What to watch

The next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.

Bull case
  • Phase 1 data showed that a single 36 mg dose of PRX-115 kept mean plasma uric acid levels below the 6.0 mg/dL therapeutic target for up to 12 weeks, suggesting potential for every-3-months or less frequent dosing versus every-2-weeks for Krystexxa, a major competitive advantage.
  • PRX-115 plasma levels remained measurable for up to 85 days after a single dose, supporting the potential for infrequent maintenance dosing and improved patient convenience/compliance.
  • Company management believes PRX-115 has best-in-class potential in uncontrolled gout based on its high specific activity, prolonged half-life, and reduced immunogenicity profile from the ProCellEx platform.
Bear case
  • PRX-115 faces entrenched competition from Krystexxa (pegloticase), the only FDA-approved uricase for uncontrolled gout, which was strengthened by FDA approval of methotrexate co-administration in 2022 to reduce infusion reactions and improve response rates.
  • Phase 2 topline data is not expected until H2 2027, leaving a long period without a binary catalyst. The stock could drift or be subject to macro/sentiment swings in the interim.
  • Uricase therapies carry inherent safety risks including infusion reactions and immunogenicity. PRX-115's PEGylated design aims to mitigate these, but Phase 2 data will be needed to confirm a differentiated safety profile.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market. FDA approved May 2023, EU approved (initial regimen), with the every-four-weeks EU dosing regimen approved March 2026.

Elfabrio pegunigalsidase alfa Updated Nov 11

What to watch

Elfabrio is an approved, revenue-generating drug with growing sales, but the stock's next major binary catalyst is the separate PRX-115 Phase 2 gout readout in H2 2027. For Elfabrio specifically, watch quarterly revenue trends and any announcement of a US filing for the every-four-weeks dosing regimen, which would be a positive catalyst. The Q4 2026 earnings (expected early 2027) will provide the next update on commercial traction.

Bull case
  • Elfabrio revenue is growing rapidly: Protalix reported Q3 2026 total revenue of $21.9M (beating ~$12M consensus) and $75.6M year-to-date, up from $43.6M in the prior-year period, with net income of $4.0M for the quarter.
  • The EU approval of every-four-weeks dosing (March 2026) is a competitive advantage that could drive market share gains by reducing infusion burden for stable patients, and triggered a $25M milestone payment from Chiesi.
  • Management targets 15-20% of the Fabry market by 2031 in a projected $3.2B total addressable market, which would imply meaningful Elfabrio-related revenue growth and royalty streams for Protalix.
Bear case
  • Elfabrio faces strong competition from Sanofi's well-established Fabrazyme (agalsidase beta) ERT and BioMarin's oral Galafold (migalastat), which is more convenient for the subset of patients with amenable mutations and may limit Elfabrio's addressable population.
  • BioMarin inked a deal in October 2026 to license another Fabry candidate, signaling potential future competition that could pressure Elfabrio's market share before it reaches peak sales.
  • The every-four-weeks dosing regimen is approved only in the EU, not the US, limiting its competitive differentiation in the larger US market.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2012.

Elelyso taliglucerase alfa Updated Nov 11

What to watch

Elelyso is not a Protalix revenue driver and has no upcoming catalysts tied to PLX. Investors should focus on Protalix's current commercial product Elfabrio (partnered with Chiesi) and the Phase 2 PRX-115 readout expected in H2 2027 for the stock's next binary catalyst.

Bull case
  • Elelyso was the first FDA-approved plant-cell-produced therapeutic, validating Protalix's ProCellEx platform technology.
  • The drug remains a commercial product for Pfizer, providing ongoing validation of the platform even though Protalix no longer shares in revenue.
  • Protalix's sale of its Elelyso stake to Pfizer in 2015 provided capital that helped fund development of its current pipeline (Elfabrio, PRX-115).
Bear case
  • Protalix sold its entire 40% economic interest in Elelyso to Pfizer in October 2015, so the drug contributes zero revenue to PLX today.
  • Elelyso faces entrenched competition from Sanofi/Genzyme's Cerezyme (imiglucerase) and Shire's Vpriv (velaglucerase alfa) in the Gaucher ERT market.
  • As a legacy divested asset, Elelyso has no bearing on Protalix's current valuation or investment thesis.
● neutral
Impact
PhasePreclinical / Discovery
Time to marketNot stated

PRX-119 Updated Nov 11

What to watch

PRX-119 is too early-stage to drive a binary event. Watch Protalix's Q4 2026 revenue to see if full-year guidance of $78M-$83M is achievable, and monitor PRX-115 Phase 2 RELEASE study top-line results expected in H2 2027 for the next pipeline catalyst.